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β-Secretase is an attractive target of amyloid-reduction 
therapy for Alzheimer’s disease. Currently, no efficacy 
data is available from clinical trials of β-secretase 
inhibitors. Treating young transgenic Tg2576 mice with 
a brain-penetrating β-secretase inhibitor reduced brain 
amyloid-β by about 50% and rescued the age-related 
cognitive decline. Implications from these model 
studies on the design of clinical trials are discussed 
herein. 
 
Since the identification of β-secretase (memapsin 2, 
BACE1) more than a decade ago, significant research 
effort from many laboratories around the world has 
been directed towards the development of inhibitor 
drugs against this β-secretase as a potential treatment of 
Alzheimer’s disease (AD) [1]. The initial excitement 
and optimism were understandable. Since amyloid-β 
(Aβ) is an important driving force in AD pathogenesis, 
clinical intervention to reduce its production would be a 
logical therapeutic approach. Toward this end, the 
inhibition of β- or γ-secretase are the best choices for 
drug development, as these two proteases represent the 
first and second steps in the processing of amyloid 
precursor protein leading to Aβ production.  
 
Inhibitor drugs for γ-secretase have exhibited toxicity 
problems in several clinical trials which appear to be 
rooted in the many important physiological functions of 
this protease, and possibly in the lack of alternative 
pathways to process its natural substrates when γ-
secretase is inhibited.  These  are fundamental problems 
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inherent to this target and have evaded practical   
solutions thus far. β-Secretase, on the other hand, is 
devoid of many of these problems. The inhibition of this 
first step in Aβ production may avoid other harmful late 
events in AD pathogenesis. Deletion of the β-secretase 
gene to eliminate Aβ production resulted in only minor 
phenotype changes in mice, suggesting that a partial 
reduction of Aβ generation by β-secretase inhibitors 
could be safe in clinical treatments. In addition, as an 
aspartic protease, β-secretase enjoys a successful 
precedence in the development of HIV protease 
inhibitor drugs used today.  
 
The attractiveness of β-secretase as a drug target, 
however, has not translated into rapid pharmaceutical 
development. A decade after the target discovery, only a 
few drug candidates have entered the early phases of 
clinical trials and no successful demonstration of 
efficacy has been reported in human trials. The slow 
pace of pharmaceutical development coupled with the 
suspension of a number of β-secretase inhibitor projects 
in major companies, have earned β-secretase a perhaps 
deserving reputation of being a difficult target. In other 
words, it has been difficult to develop β-secretase 
inhibitors that possess all required properties such as 
blood–brain barrier penetration, selectivity, pharmaco-
kinetic characteristics and toxicity. To a large extent, 
these difficulties are unique to this target. β-Secretase 
has a large active-site area for inhibitor binding. Yet it 
permits relatively limited options for designing small, 
potent and selective inhibitors and thus renders 
   
www.impactaging.com                    14                                         AGING, January 2011, Vol.3 No.1ineffective some of the traditional drug discovery tools, 
such  as  automated  screening  of  chemical  libraries or 
computer assisted inhibitor design.  
 
However, by using crystal structure based inhibitor 
design, more drug-like inhibitors have emerged. At least 
three pharmaceutical companies have conducted Phase I 
trials for their inhibitor candidates; but convincing 
efficacy results from clinical trials will take years of 
future efforts. It is therefore appropriate to ask, what we 
have learned from therapeutic model, such as a 
transgenic AD mouse with β-secretase inhibitors? 
Although AD mice do not accurately duplicate human 
AD, they do share some early human AD features, 
which include excess production of brain Aβ, a decline 
of cognitive performance with age, and the development 
of amyloid plaques in the brain at middle-late age. AD 
mice do not progress to dementia as in human AD. 
However, for testing an amyloid reduction therapy 
using β-secretase inhibitors, the AD syndromes in these 
mice can produce useful insights to human treatments. 
At this stage in β-secretase inhibitor development, it 
would be informative to learn if these AD-like 
syndromes can be rescued in AD mice by partial 
amyloid reduction. 
 
Chang et al. reported recently [2] that the administration 
of β-secretase inhibitor GRL-8234 rescued age-related 
cognitive decline and reduced brain amyloid burden in 
transgenic AD mice Tg2576. In this mouse strain, 
excess Aβ produced in the brain leads to cognitive 
decline starting at about 6 months of age and continues 
through life. At about 10 months of age, amyloid 
plaques start to appear in the brain. The age-related 
cognitive decline in this strain of AD mice [3], which is 
dependent on the overproduction of Aβ in the brain, is 
the most stringent efficacy criteria available in AD 
mouse model. In the studies of Chang et al., AD mice 
were continuously infused with GRL-8234 which 
reduced brain and plasma Aβ by about 50% of the 
controls. In three separate experiments in which the 
starting age of the mice ranged from 5.5 to 9 months, 
differences in the cognitive performance between the 
treated and the control mice were seen only after a 
period ranging from about 4 to 7 months. Treatments of 
shorter periods or starting treatment at an older age (18 
months) failed to show the benefit of cognitive rescue. 
In all the experiments which resulted in cognitive 
rescue, the reduction of brain amyloid was about 50%.  
 
These results are encouraging and several interesting 
points have emerged from this study. First, a partial 
reduction of Aβ production and brain plaque load of 
about 50% was sufficient to rescue the cognitive decline 
in this model. The current results appear to suggest that 
the cognitive decline can be significantly improved in 
spite of some excess of brain Aβ. Conceivable 
mechanisms to accommodate these findings may 
include the presence of an Aβ threshold for cognitive 
decline or partial Aβ reduction may delay the onset of 
cognitive decline. Regardless of the mechanism, 
efficacy of cognitive rescue by partial Aβ reduction 
would be good news if it is confirmed by clinical 
studies. Second, there was no overt toxicity associated 
with treatment over a 7 month time period and no 
significant accumulation of APP in the brain of treated 
mice, a potential mechanism based side effect. The 
latter observation suggests that the known alternative 
APP processing pathway by α–secretase was 
sufficiently active to dispose an overproduced β-
secretase substrate. Third, it took several months, which 
was somewhat surprising to manifest cognitive rescue 
in inhibitor treated mice. One explanation is that the 
cognitive decline in Tg2576 is known to be a slow 
process. Thus, the differential of cognitive performance 
between the treated and control groups would require a 
long time. Fourth, inhibitor treatment of old mice about 
6 months after the appearance of brain plaque failed to 
show the benefit. This failure may stem from the fact 
that the old mice became incompetent for cognitive tests 
before the rescue could be demonstrated. Another 
possibility is that some of the amyloid existed in the 
brain of old mice prior to the beginning of the treatment 
may serve as a source of Aβ in a partial resolubilization 
process. This may have kept Aβ levels higher than 
expected and thus would require an even longer time to 
show cognitive rescue. It is perhaps worthwhile to 
consider the last two points in the setting of human 
clinical trials. In AD patients, cognitive performance 
declines slowly in general and amyloid plaques are 
present in the later stages of the disease. For clinical 
trials of β-secretase inhibitor drugs, cognitive tests are 
the only efficacy criteria acceptable for the FDA. 
Therefore, a Phase II/III trial with early stage AD 
patients over a long trial period will have the best 
chance to avoid the potential problems discussed above. 
In addition, testing β-secretase inhibitor drugs in an 
amyloid reduction concept, early stage AD patients 
would have less brain destruction and inflammation, 
which is not expected to be reversed quickly by β-
secretase inhibitors and may obscure the benefit of the 
drugs. It will be of interest to study the same β-secretase 
inhibitor in both AD mice and human efficacy trials. A 
predictive model may contribute to the planning and 
decisions on long, costly human trials. 
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